Journal of the Association of Nurses in AIDS Care
Volume 18, Issue 3 , Pages 74-86 , May 2007

New Insights Into HIV Resistance Testing: Nursing Guidelines and Implications

References 

  1. Buckheit RW. Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opinion on Investigational Drugs. 2004;12:933–958
  2. Emery S, Hales G, Birch C, Crowe S, Hoy J, Workman C, et al. (February). CREST—A randomized comparison of genotype and phenotype plus virtual phenotype (VircoGen II). 2003;(Abstract No. 592). Conference on Retroviruses and Opportunistic Infections, Boston, MA.
  3. Graham N, Peeters M, Verbiest W, Harrigan R, Larder B. (February). The virtual phenotype is an independent predictor of clinical response. 2001;(Abstract No. 524). Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
  4. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. Journal of the American Medical Association. 2002;288:181–188
  5. Haubrich RH. Resistance and replication capacity assays: Clinical utility and interpretation. Topics in HIV Medicine. 2004;12:52–56
  6. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002;16:F33–F40
  7. Hicks C, Pilcher C, Eron J, Weintrob A, Lennox J, Giner J. (February). Changing patterns of transmitted resistance among patients with primary HIV infection in North Carolina from 1998 to 2003: Evidence for the importance of improved HAART. 2004;(Abstract No. 682). Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
  8. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D’Aquila RT. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society–USA Panel. Clinical Infectious Disease. 2003;37:113–128
  9. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D’Aquila RT, Demeter LM. Update of the drug resistance mutations in HIV-1: 2004. Topics in HIV Medicine. 2004;12:119–124
  10. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-Drug Resistance among Patients Recently Infected with HIV. New England Journal of Medicine. 2002;347:385–394
  11. Panel on Antiretroviral Guidelines for Adults and AdolescentsDepartment of Health and Human Services. In: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 2006;p. 1–113October 10, 2006, Retrieved April 17, 2007, from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsSGL.pdf
  12. Perez-Elias MJ, Garcia I, Munoz V. (July). A randomized, prospective study of phenotype (P) versus virtual phenotype (virtualP) testing for patients failing antiretroviral therapy (ARVT): Final analysis. 2002;(Abstract No. B10421). International Conference on AIDS, Barcelona, Spain.
  13. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393–1401
  14. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. Antiviral Therapy. 2004;9:829–848
  15. Wainberg, M. (2004). Nucleoside-associated mutations in HIV-1 reverse transcriptase: Mechanisms, mutational patterns, and management: Northwestern University Feinberg School of Medicine and iMedOptions, LLC. Retrieved September 2, 2006 from http://www.clinicaloptions.com/HIV/Treatment%20Updates/Resistance%20Testing/Modules/testing_wainberg.aspx
  16. Zolopa, A. D., & Kuritzkes, D. R. (2006). Role of antiretroviral resistance testing in clinical practice: Postgraduate Institute for Medicine and Clinical Care Options, LLC. Retrieved April 17, 2007, from http://Clinicaloptions.com/HIV/Management%20series/Resistance/Modules/Assays.aspx
  17. Zolopa, A., Lazzeroni, A., Rinehart, A., & Kuritzkes, D. (2002). The GUESS study: An international evaluation of the accuracy, precision consistency of expert HIV-1 genotype interpretation. Retrieved February 2, 2005, from http://www.aegis.com/conferences/14wac/ThOrB1385.html

PII: S1055-3290(07)00105-7

doi: 10.1016/j.jana.2007.03.003

Journal of the Association of Nurses in AIDS Care
Volume 18, Issue 3 , Pages 74-86 , May 2007

Article Tools

* Image Usage & Resolution